.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Accenture
Queensland Health
Argus Health
Fish and Richardson
Mallinckrodt
Covington
Novartis
Merck
Daiichi Sankyo

Generated: July 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Pellet formulation for the treatment of the intenstinal tract
Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:13/586,585
Patent Claims: 1. A controlled release pellet formulation, comprising 1) homogeneously dispersed 5-aminosalicylic acid in a core comprising a polymer matrix, wherein the polymer matrix is essentially insoluble in the intestinal tract and permeable to artificial intestinal juice, and wherein the polymer matrix comprises at least 1% by weight of the total weight of the core; and 2) an enteric coating; wherein, when administered to humans, the mean maximal plasma concentration of the 5-aminosalicylic acid is reached at about 4 hours after administration.

2. The controlled release pellet formulation of claim 1, wherein about 10-30% of the 5-aminosalicyclic acid is released from the formulation in 30 minutes at 37.degree. C. in artificial intestinal juice at a pH of about 6.8.

3. The controlled release pellet formulation of claim 1, wherein about 40-60% of the 5-aminosalicyclic acid is released from the formulation in about 2 hours at 37.degree. C. in artificial intestinal juice at a pH of about 6.8.

4. The controlled release pellet formulation of claim 1, wherein, when administered to humans, the mean maximal plasma concentration of acetyl-5-aminosalicylic acid is at about 5 hours after administration.

5. The controlled release pellet formulation of claim 1, wherein, when administered to humans, the ratio of the mean plasma concentration of 5-aminosalicyclic acid to the mean plasma concentration of acetyl-5-aminosalicylic acid at about 4 hours after administration is about 1:2.

6. The controlled release pellet formulation of claim 1, wherein, when administered to humans, the ratio of the mean plasma concentration of 5-aminosalicyclic acid to the mean plasma concentration of acetyl-5-aminosalicylic acid at about 6 hours after administration is about 1:3.

7. The controlled release pellet formulation of claim 1, wherein, when administered to humans, the ratio of the mean plasma concentration of 5-aminosalicyclic acid to the mean plasma concentration of acetyl-5-aminosalicylic acid at about 8 hours after administration is about 1:5.

8. The controlled release pellet formulation of claim 1, wherein, when the controlled release pellet formulation is administered to humans, the mean plasma concentration of 5-aminosalicyclic acid is less than about 1564 ng/ml at about 5 hours after administration.

9. The controlled release pellet formulation of claim 1, wherein, when administered to humans, the mean plasma concentration of 5-aminosalicyclic acid is less than about 924 ng/ml at about 6 hours after administration.

10. The controlled release pellet formulation of claim 1, wherein, when the controlled release pellet formulation is administered to humans, the mean plasma concentration of acetyl-5-aminosalicylic acid is less than about 2511 ng/ml at about 5 hours after administration.

11. The controlled release pellet formulation of claim 1, wherein, when administered to humans, the mean plasma concentration of acetyl-5-aminosalicylic acid is less than about 2243 ng/ml at about 6 hours after administration.

12. A controlled release pellet formulation comprising: 1) 5-aminosalicyclic acid in a core comprising a polymer matrix, wherein the polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluid, and wherein the polymer matrix comprises at least 1% by weight of the total weight of the core; and an enteric coating; wherein about 10-30% of the 5-aminosalicyclic acid is released from the formulation in about 30 minutes at 37.degree. C. in artificial intestinal juice at a pH of about 6.8.

13. The controlled release pellet formulation of claim 12, wherein about 40-60% of the 5-aminosalicyclic acid is released from the formulation in about 2 hours.

14. The controlled release pellet formulation of claim 12, wherein the 5-aminosalicyclic acid is homogeneously dispersed in the polymer matrix.

15. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the ratio of the mean plasma concentration of 5-aminosalicyclic acid to the mean plasma concentration of acetyl-5-aminosalicylic acid at about 4 hours after administration is about 1:2.

16. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the ratio of the mean plasma concentration of 5-aminosalicyclic acid to the mean plasma concentration of acetyl-5-aminosalicylic acid at about 6 hours after administration is about 1:3.

17. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the ratio of the mean plasma concentration of 5-aminosalicyclic acid to the mean plasma concentration of acetyl-5-aminosalicylic acid at about 8 hours after administration is about 1:5.

18. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the mean plasma concentration of 5-aminosalicyclic acid is less than about 1293 ng/ml at about 4 hours after administration.

19. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the mean plasma concentration of 5-aminosalicyclic acid is less than about 1564 ng/ml at about 5 hours after administration.

20. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the mean plasma concentration of 5-aminosalicyclic acid is less than about 924 ng/ml at about 6 hours after administration.

21. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the mean plasma concentration of acetyl-5-aminosalicylic acid is less than about 1651 ng/ml at about 4 hours after administration.

22. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the mean plasma concentration of acetyl-5-aminosalicylic acid is less than about 2511 ng/ml at about 5 hours after administration.

23. The controlled release pellet formulation of claim 12, wherein, when administered to humans, the mean plasma concentration of acetyl-5-aminosalicylic acid is less than about 2243 ng/ml at about 6 hours after administration.

24. A controlled release pellet formulation comprising: 1) 5-aminosalicyclic acid in a core comprising a polymer matrix, wherein the polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluid, and wherein the polymer matrix comprises at least 1% by weight of the total weight of the core; and 2) an enteric coating; wherein the pellets have a particle size of 0.1 mm to 3 mm.

25. The controlled release pellet formulation of claim 24, wherein the pellets have a particle size of about 0.5 to about 1.0 mm.

26. The controlled release pellet formulation of claim 24, wherein the pellets have a particle size of about 1 mm.

27. The controlled release pellet formulation, of claim 1, wherein the pellets have a particle size of 0.1 mm to 3 mm.

28. The controlled release pellet formulation of claim 1, wherein the pellets have a particle size of about 1 mm.

29. The controlled release pellet formulation, of claim 12, wherein the pellets have a particle size of 0.1 mm to 3 mm.

30. The controlled release pellet formulation of claim 12, wherein the pellets have a particle size of about 1 mm.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Mallinckrodt
Argus Health
Novartis
Fuji
QuintilesIMS
Medtronic
Merck
Queensland Health
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot